Obesity
149 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Agbs for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Apitegromab for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| arabinoxylan for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATR-258 for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autoinjector + Maridebart Cafraglutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AZD6234 for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Berobenatide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Beta-glucan addition to a restricted calorie of meal replacements and carbohydrate diet. for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BI 1820237 for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BI 1820237 + Placebo for BI 1820237 + Placebo for BI 456906 + Survodutide for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BI 3034701 for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bimagrumab for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| bis-octanoyl (R)-1,3-butanediol (C8 ketone di-ester) for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bread with added beta-glucans for obesity, abdominal | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cagrilintide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Cagrilintide and Semaglutide + Placebo for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CagriSema for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| CagriSema (Cagrilintide B + semaglutide I) for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CagriSema (Cagrilintide B + semaglutide I) + Low Energy Diet for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Calorie restriction via total food replacement for obesity, morbid | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ci + ends for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CI + No ENDS for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clazakizumab for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Comprehensive weight loss + Enhanced lifestyle changes + Naltrexone-Bupropion + Phentermine-Topiramate for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Comprehensive weight loss + Enhanced lifestyle changes + Semaglutide + Tirzepatide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Continous Glucose Monitor (CGM) + Low-calorie diet + Personalized exercise program for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Counseling + Phone calls + Self-monitoring tools + Text Messages for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cryolipolysis for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| cryolipolysis and aerobic exercise for obesity, abdominal | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cryolipolysis device for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Culturally Tailored Diabetes Prevention Program for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Culturally Tailored Diabetes Prevention Program + Culturally Tailored DPP Enhanced with Socioeconomic Supports for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Danuglipron for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin plus Glucophage (MET ER) for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ecnoglutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 8 |
| Elecoglipron for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Electronic Cigarettes (EC) for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Eloralintide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 13 |
| Eloralintide + Macupatide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Eloralintide + Tirzepatide for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| eloralintide and tirzepatide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Empagliflozin for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ends + ni for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EQW plus DAPA for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exenatide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Food-based diet for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Formula diet for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Formulation A + Formulation B6 for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GnRH antagonist + Letrozole for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Green coffee + beta-glucan for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Green coffee extract for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + naltrexone and bupropion (combination) for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + Phentermine-Topiramate for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + Semaglutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| gut-brain axis (GLP-1)-activating food carbohydrate for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-intensity Mediterranean diet intervention for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HRS9531 for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| HRS9531 Injection for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| HRS9531 injection;Placebo for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IN-B00009 for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intensive lifestyle Intervention + Meal replacement system for obesity | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intraoral Negative Pressure Therapy + Oral Appliances + Positional Therapy + Surgery + Tongue Muscle Strength Training for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| K-757 120 mg BID and K-833 100 mg BID for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| K-757 120 mg BID and matching placebo to K-833 for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| K-757 and K-833 for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| K-757 and K-833 BID + K-757 and K-833 QD for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Liraglutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Liver-expressed antimicrobial peptide 2 for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| low calorie diet + Phentermine/topiramate for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Macupatide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Maridebart Cafraglutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Matching placebo to K-757 and matching placebo to K-833 for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Placebo-Garetosmab + Matching Placebo-Trevogrumab + Semaglutide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Placebo-Garetosmab + Matching Placebo-Trevogrumab + Semaglutide + TREVOGRUMAB for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Placebo-Garetosmab + Semaglutide + TREVOGRUMAB for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Placebo-Trevogrumab + Semaglutide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Placebo-Trevogrumab + Semaglutide + TREVOGRUMAB for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Placebo-Trevogrumab + Semaglutide + TREVOGRUMAB + GARETOSMAB for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mazdutide for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Meal Replacement Therapy for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MET097 for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MKP10241 for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NI + No ENDS for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nicotine replacement therapy (NRT) for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NNC0487-0111 for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oral BGE-102 for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Orforglipron for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 16 |
| Oxytocin for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Oxytocin for pediatric obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pemvidutide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Petrelintide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-06882961 (Cohort 3) for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-06882961 (Cohorts 1 and 2) for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-08653944 for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phentermine for pediatric obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phentermine / Topiramate Oral Product for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phentermine-Topiramate for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phentermine-Topiramate ER for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Photobiomodulation for obesity, morbid | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo (matched to semaglutide) + Zenagamtide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Eloralintide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Eloralintide + Macupatide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Eloralintide + Tirzepatide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + MAZDUTIDE for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Naperiglipron for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Oxytocin for obesity | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Reduced-calorie diet + Tirzepatide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Standardized diet and physical activity counseling throughout the study. + Retatrutide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo Nasal Spray for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| placebo with matching dosage + ECNOGLUTIDE for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Qsymia for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Qsymia 11.25Mg-69Mg Extended Release Capsule + Qsymia 15Mg-92Mg Extended Release Capsule + Qsymia 3.75Mg-23Mg Extended Release Capsule + Qsymia 7.5Mg-46Mg Extended Release Capsule for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Qsymia and lifestyle management therapy for pediatric obesity | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RAY1225 for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| responsive neurostimulation for obesity, morbid | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 12 |
| Ribupatide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 20 |
| Semaglutide for pediatric obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide + BIMAGRUMAB for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide + Cagrilintide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Semaglutide + TREVOGRUMAB for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide + TREVOGRUMAB + GARETOSMAB for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Structured weight-loss program for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Survodutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 15 |
| Tirzepatide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 23 |
| Total Diet Replacement for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Total Diet Replacement (TDR) Program for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Trevogrumab for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UBT251 for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| UBT251 Injection 2.0 mg and UBT251 Injection Placebo for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UBT251 Injection 4.0 mg for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UBT251 Injection 6.0 mg for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UBT251 Injection 6.0 mg and UBT251 Injection Placebo for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ultrasound lipolysis for obesity, abdominal | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VI-0521 for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VI-0521 for obesity, morbid | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VI-0521 Mid Dose for pediatric obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VI-0521 oral capsule for pediatric obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VI-0521 Top Dose for pediatric obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Virtual Weight Management Coaching + Semaglutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| WVE-007 for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zeltiq CoolSculpting device for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |